StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Teva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'
October 4, 2017 12:17 PM
Barclays lowered its price target on Teva Pharma (NYSE: TEVA) to $21.00 (from $23.00) while ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley
October 5, 2017 8:58 AM
Momenta Phama (MNTA) Declines to Comment on Status of Generic Capoxone 40mg - Bloomberg
October 4, 2017 9:53 AM
Teva Pharma (TEVA): Downside From $16 Likely, Cutting PT - Cowen
October 4, 2017 9:28 AM
Teva Pharma (TEVA) Says it Remains Confident in Patient and Physician Loyalty to COPAXONE
October 4, 2017 9:28 AM
Wall St. extends run of record highs; services data upbeat
October 4, 2017 7:54 AM
Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic Approval
October 4, 2017 7:27 AM
Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - Mizuho
October 4, 2017 7:02 AM
Momenta Phama (MNTA) on Watch After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone
October 4, 2017 6:42 AM
Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of Copaxone
October 4, 2017 6:20 AM
Teva (TEVA) Shares Pressured After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone
October 4, 2017 6:14 AM
